¼¼°èÀÇ ¾ÆÅäÇÇ ÇǺο° Ä¡·áÁ¦ ½ÃÀå(2024-2028³â)
Global atopic dermatitis drugs market 2024-2028
»óǰÄÚµå : 1502450
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,547,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,676,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Å×Å©³ªºñ¿À(Technavio)´Â ¾ÆÅäÇÇ ÇǺο° Ä¡·áÁ¦ ½ÃÀåÀÌ 2023³âºÎÅÍ 2028³â±îÁö 62¾ï 480¸¸ ´Þ·¯, ¿¹Ãø ±â°£ µ¿¾È 10.87%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

¾ÆÅäÇÇ ÇǺο° Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´ë»óÀ¸·Î ÇÑ º¥´õ ºÐ¼® µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ¾ÆÅäÇÇ ÇǺο°ÀÇ ³ôÀº À¯º´·ü, ÀÇ·áºñ ÁöÃâ Áõ°¡, °­·ÂÇÑ R&D ÆÄÀÌÇÁ¶óÀÎÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2024
Á¾·á ¿¬µµ 2028
¿¹Ãø ±â°£ 2024-2028
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â ´ëºñ 2024³â 9.53%
CAGR 10.87%
ÁõºÐ ±Ý¾× 62¾ï 480¸¸ ´Þ·¯

ÀÌ º¸°í¼­´Â ÇâÈÄ ¸î ³â µ¿¾È ¾ÆÅäÇÇ ÇǺο° Ä¡·áÁ¦ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÒ ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î Àü·«Àû ÆÄÆ®³Ê½Ê°ú Àμö¸¦ ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, ÁöÁ¤ÇÐÀû ºÒÈ®½Ç¼º°ú ¾ÆÅäÇÇ ÇǺο°¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥µµ ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå »óȲ

Á¦3Àå ½ÃÀå ±Ô¸ð Æò°¡

Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦5Àå Five Forces ºÐ¼®

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­ : Åõ¿© °æ·Îº°

Á¦7Àå ½ÃÀå ¼¼ºÐÈ­ : ¾à¹° Á¾·ùº°

Á¦8Àå °í°´ »óȲ

Á¦9Àå Áö¿ªº° »óȲ

Á¦10Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ

Á¦11Àå °æÀï »óȲ

Á¦12Àå °æÀï ºÐ¼®

Á¦13Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Technavio has been monitoring the atopic dermatitis drugs market and is forecast to grow by USD 6204.8 mn during 2023-2028, accelerating at a CAGR of 10.87% during the forecast period. Our report on the atopic dermatitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of atopic dermatitis, increasing healthcare expenditure, and strong R and D pipeline.

Technavio's atopic dermatitis drugs market is segmented as below:

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20249.53%
CAGR10.87%
Incremental Value$6204.8mn

By Route Of Administration

By Drug Class

By Geography

This study identifies the strategic partnerships and acquisitions as one of the prime reasons driving the atopic dermatitis drugs market growth during the next few years. Also, geopolitical uncertainties and programs to promote awareness of atopic dermatitis will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the atopic dermatitis drugs market covers the following areas:

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading atopic dermatitis drugs market vendors that include AbbVie Inc., Arcutis Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, BiomX Inc., Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, and Viatris Inc.. Also, the atopic dermatitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Route of Administration

7 Market Segmentation by Drug Class

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Opportunity/Restraints

11 Competitive Landscape

12 Competitive Analysis

13 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â